Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.
Leypoldt LB, Tichy D, Besemer B, Hanel M, Raab MS, Mann C, Munder M, Reinhardt HC, Nogai A, Gorner M, Ko YD, Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Pozek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. Among authors: tichy d. Future Oncol. 2024 Sep 30:1-15. doi: 10.1080/14796694.2024.2402639. Online ahead of print. Future Oncol. 2024. PMID: 39345094
Development and characterization of a bacteriophage cocktail with high lytic efficacy against field-isolated Salmonella enterica.
Aguilera M, Tobar-Calfucoy E, Rojas-Martínez V, Norambuena R, Serrano MJ, Cifuentes O, Zamudio MS, San Martín D, Lara P, Sabag A, Zabner M, Tichy D, Camejo P, León L, Pino M, Ulloa S, Rojas F, Pieringer C, Muster C, Castillo D, Ferreira N, Avendaño C, Canaval M, Pieringer H, Cifuentes P, Cifuentes Muñoz N. Aguilera M, et al. Among authors: tichy d. Poult Sci. 2023 Dec;102(12):103125. doi: 10.1016/j.psj.2023.103125. Epub 2023 Sep 18. Poult Sci. 2023. PMID: 37879168 Free PMC article.
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.
Leypoldt LB, Tichy D, Besemer B, Hänel M, Raab MS, Mann C, Munder M, Reinhardt HC, Nogai A, Görner M, Ko YD, de Wit M, Salwender H, Scheid C, Graeven U, Peceny R, Staib P, Dieing A, Einsele H, Jauch A, Hundemer M, Zago M, Požek E, Benner A, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. Among authors: tichy d. J Clin Oncol. 2024 Jan 1;42(1):26-37. doi: 10.1200/JCO.23.01696. Epub 2023 Sep 27. J Clin Oncol. 2024. PMID: 37753960 Free PMC article.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: tichy d. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial.
Leypoldt LB, Besemer B, Asemissen AM, Hänel M, Blau IW, Görner M, Ko YD, Reinhardt HC, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Jauch A, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel KC. Leypoldt LB, et al. Among authors: tichy d. Leukemia. 2022 Mar;36(3):885-888. doi: 10.1038/s41375-021-01431-x. Epub 2021 Nov 3. Leukemia. 2022. PMID: 34732857 Free PMC article. Clinical Trial. No abstract available.
Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial.
Klein EM, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC, Benner A, Bertsch U, Akhavanpoor M, Besemer B, Munder M, Lindemann HW, Hose D, Seckinger A, Luntz S, Jauch A, Elmaagacli A, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H, On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg. Klein EM, et al. Among authors: tichy d. Cancers (Basel). 2021 Sep 28;13(19):4856. doi: 10.3390/cancers13194856. Cancers (Basel). 2021. PMID: 34638344 Free PMC article.
33 results